About
NASH
PPAR AGONISTS
- NASH PPARs Science
- Pan-PPAR Agonists
Resources
- PanNash initiative is the free library to increase awareness and disseminate knowledge related to NASH as a multisystem disease. Find the latest research, multimedia content, free videos, publications and reports.
  
  SLIDES
  
  Commented articles
  
  Video Library
Contact Us
sign up for newsletter
Become a Member

NAFLD/NASH as a metabolic disease: improving patients outcomes

Prof. Maarten Tushuizen, Netherlands, discusses the current treatment strategies for non-alcoholic fatty liver disease (NAFLD) and explains as well as future therapeutic approaches. Non-invasive tests (NITs) for staging the continuum of NAFLD / NASH are critical as well as establishing effective care pathways.

Play Video

Would you like to read more?

Maarten E. Tushuizen

Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.

SUBSCRIBE & FOLLOW US

Subscribe Our Newsletter To Get the Lastest Updates

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Users

SLIDES

Commented articles

Video Library

Would you like to read more?

Maarten E. Tushuizen

SUBSCRIBE & FOLLOW US

Subscribe Our Newsletter To Get the Lastest Updates

Related Videos

NASH Treatment in 2022: review of current and future therapies for non-alcoholic steatohepatitis

NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise

Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)